Search

Aim: Valuable and convenient prognostic predictors are essential for targeted therapy of non–small cell lung cancer (NSCLC). Patients with early‐stage cancer and EGFR mutations who's neutrophils‐to‐lymphocytes rate (NLR) could be prognostic factor to evaluate efficacy. However, the prognostic role of NLR in patients receiving ALK inhibitors has not been established. Additionally, the relation between the efficacy of ALK inhibitors and derived NLR (dNLR), platelets‐to‐lymphocytes rate (PLR), white blood cells (WBC) and hemoglobin (HGB) are still unknown. Methods: This is a retrospective single‐center study and enrolled 113 staged IIIB–IV ALK‐positive NSCLC patients who had received crizotinib treatment. Pretreatment NLR, dNLR, PLR, WBC, HGB were collected and calculated. Cox regression analysis were conducted to study the prognostic roles of NLR, dNLR, PLR, WBC, and HGB on progression‐free survival (PFS) and overall survival (OS). Z‐test was utilized to identify the difference among all predictive factors' receiver‐operating characteristics (ROC) curves. Results: The median PFS and OS were 10.1 and 23.4 months. Elevated NLR, dNLR, PLR and decreased HGB were associated with worse PFS (95% confidence interval [CI], 1.078–2.304, P = 0.018; 95% CI, 1.043–2.222, P = 0.028; 95% CI, 1.257–2.757, P = 0.002; 95% CI, 0.368–0.843, P = 0.005, respectively) and OS (95% CI, 1.698–5.721, P < 0.001; 95% CI, 1.273–3.984, P = 0.005; 95% CI, 2.174–6.347, P < 0.001; 95% CI, 0.246–0.710, P = 0.001, respectively). Z‐test revealed there were no significant differences between single factors or combination of them to predict the efficacy. Conclusions: Trend of NLR, dNLR, PLR and WBC could be used to identify patients progress status in ALK‐positive NSCLC patients receiving crizotinib. Combination of all biomarkers is no superior to single biomarker. [ABSTRACT FROM AUTHOR]

Aim: Most epidermal growth factor receptor (EGFR) gene mutations affecting exon 19 (inframe deletions; 19 Del) and 21 (L858R), while the rest (referred as uncommon EGFR mutation) have not been fully described due to their rarity. Here we present a retrospective study that investigated clinical characteristics and outcome of patients with different EGFR mutations. Methods: We retrospectively analyzed the EGFR mutation pattern and its association with clinical‐pathological characteristics from 100 cases of nonsmall‐cell lung cancer (NSCLC) harboring EGFR mutations, and compiled the genotype response data for NSCLC patients with common and uncommon EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs). Patients with advanced EGFR‐mutated NSCLC were enrolled and treated with icotinib (oral administration, 125 mg, thrice per day). Results: Among 100 patients, 85 and 15 had common and uncommon mutations, respectively. Four patients had a single mutation in 18 or 20 exon, and 11 had a complex mutation with del‐19 or L858R. There was no significant association between the presence of different mutation type and the type of any clinical and pathological characteristics. Prolonged but not significant progression‐free survival (PFS) was noted in patients with common EGFR mutations (18.07 [14.00–26.23] vs 12.9 [8.43–23.27], P = 0.056). Patients without brain metastases had increased PFS to icotinib than those with brain metastases (18.07 [95% confidence interval, CI 14.77–27.03] vs 13.17 [95% CI 8.63–22.63], P = 0.038). Conclusion: Uncommon EGFR mutations comprised 15% of all mutated patients, in which most were complex mutations. Compared with common EGFR mutation, uncommon EGFR mutations were associated with a modest sensitivity to EGFR TKIs. Our findings will be helpful to make clinical decision and select the appropriate therapy for EGFR‐mutated NSCLC patients. [ABSTRACT FROM AUTHOR]